138 related articles for article (PubMed ID: 17904240)
21. Biodegradation of hydrogel carrier incorporating fibroblast growth factor.
Tabata Y; Nagano A; Ikada Y
Tissue Eng; 1999 Apr; 5(2):127-38. PubMed ID: 10358220
[TBL] [Abstract][Full Text] [Related]
22. Alveolar bone regeneration using absorbable poly(L-lactide-co-epsilon-caprolactone)/beta-tricalcium phosphate membrane and gelatin sponge incorporating basic fibroblast growth factor.
Kinoshita Y; Matsuo M; Todoki K; Ozono S; Fukuoka S; Tsuzuki H; Nakamura M; Tomihata K; Shimamoto T; Ikada Y
Int J Oral Maxillofac Surg; 2008 Mar; 37(3):275-81. PubMed ID: 18262760
[TBL] [Abstract][Full Text] [Related]
23. Micro and nano-fabrication of biodegradable polymers for drug delivery.
Lu Y; Chen SC
Adv Drug Deliv Rev; 2004 Sep; 56(11):1621-33. PubMed ID: 15350292
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of a biodegradable gelatin hydrogel sponge sheet on the progression of experimental abdominal aortic aneurysms.
Miyama N; Sato A; Matsubara M; Watanabe T; Ikada Y; Satomi S
Ann Vasc Surg; 2009 Mar; 23(2):224-30. PubMed ID: 18783914
[TBL] [Abstract][Full Text] [Related]
25. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition.
Edelman ER; Nugent MA; Karnovsky MJ
Proc Natl Acad Sci U S A; 1993 Feb; 90(4):1513-7. PubMed ID: 8434012
[TBL] [Abstract][Full Text] [Related]
26. The immobilization of basic fibroblast growth factor on plasma-treated poly(lactide-co-glycolide).
Shen H; Hu X; Bei J; Wang S
Biomaterials; 2008 May; 29(15):2388-99. PubMed ID: 18313747
[TBL] [Abstract][Full Text] [Related]
27. An improved matrix-type controlled release system for basic fibroblast growth factor.
Hickey MJ; Morrison WA
Biochem Biophys Res Commun; 1994 Jun; 201(3):1066-71. PubMed ID: 8024547
[TBL] [Abstract][Full Text] [Related]
28. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
[TBL] [Abstract][Full Text] [Related]
29. Controlled delivery of bFGF to recipient bed enhances the vascularization and viability of an ischemic skin flap.
Fujihara Y; Koyama H; Ohba M; Tabata Y; Fujihara H; Yonehara Y; Takato T
Wound Repair Regen; 2008; 16(1):125-31. PubMed ID: 18211584
[TBL] [Abstract][Full Text] [Related]
30. Sustained interferon-gamma delivery from a photocrosslinked biodegradable elastomer.
Gu F; Younes HM; El-Kadi AO; Neufeld RJ; Amsden BG
J Control Release; 2005 Feb; 102(3):607-17. PubMed ID: 15681083
[TBL] [Abstract][Full Text] [Related]
31. Microfabricated drug delivery devices.
Hilt JZ; Peppas NA
Int J Pharm; 2005 Dec; 306(1-2):15-23. PubMed ID: 16253449
[TBL] [Abstract][Full Text] [Related]
32. Transendocardial and transepicardial intramyocardial fibroblast growth factor-2 administration: myocardial and tissue distribution.
Laham RJ; Post M; Rezaee M; Donnell-Fink L; Wykrzykowska JJ; Lee SU; Baim DS; Sellke FW
Drug Metab Dispos; 2005 Aug; 33(8):1101-7. PubMed ID: 15879496
[TBL] [Abstract][Full Text] [Related]
33. Biodegradable and biocompatible thermosensitive polymer based injectable implant for controlled release of protein.
Tang Y; Singh J
Int J Pharm; 2009 Jan; 365(1-2):34-43. PubMed ID: 18786623
[TBL] [Abstract][Full Text] [Related]
34. Use of human mesenchymal cells to improve vascularization in a mouse model for scaffold-based dermal regeneration.
Egaña JT; Fierro FA; Krüger S; Bornhäuser M; Huss R; Lavandero S; Machens HG
Tissue Eng Part A; 2009 May; 15(5):1191-200. PubMed ID: 18925832
[TBL] [Abstract][Full Text] [Related]
35. Development of bFGF-chitosan matrices and their interactions with human dermal fibroblast cells.
Lefler A; Ghanem A
J Biomater Sci Polym Ed; 2009; 20(10):1335-51. PubMed ID: 19622275
[TBL] [Abstract][Full Text] [Related]
36. Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model.
Layman H; Sacasa M; Murphy AE; Murphy AM; Pham SM; Andreopoulos FM
Acta Biomater; 2009 Jan; 5(1):230-9. PubMed ID: 18713669
[TBL] [Abstract][Full Text] [Related]
37. Vascularization around poly(tetrafluoroethylene) mesh with coating of gelatin hydrogel incorporating basic fibroblast growth factor.
Takaoka R; Hikasa Y; Tabata Y
J Biomater Sci Polym Ed; 2009; 20(10):1483-94. PubMed ID: 19622284
[TBL] [Abstract][Full Text] [Related]
38. A novel controlled local drug delivery system for inner ear disease.
Paulson DP; Abuzeid W; Jiang H; Oe T; O'Malley BW; Li D
Laryngoscope; 2008 Apr; 118(4):706-11. PubMed ID: 18182968
[TBL] [Abstract][Full Text] [Related]
39. Distribution of fibroblast growth factor-2 (FGF-2) within model excisional wounds following topical application.
Braund R; Hook SM; Greenhill N; Medlicott NJ
J Pharm Pharmacol; 2009 Feb; 61(2):193-200. PubMed ID: 19178766
[TBL] [Abstract][Full Text] [Related]
40. Preparation of mannan modified anionic PCL-PEG-PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity.
Gou M; Dai M; Li X; Yang L; Huang M; Wang Y; Kan B; Lu Y; Wei Y; Qian Z
Colloids Surf B Biointerfaces; 2008 Jun; 64(1):135-9. PubMed ID: 18249528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
